About h7LNhJnSDCThis author has not yet filled in any details.
So far h7LNhJnSDC has created 75 blog entries.
Cernostics Announces Groundbreaking Data Demonstrating TissueCypher® Performance for Predicting Risk of Progression to EAC in Patients with Non-Dysplastic BE
First-of-its-kind precision medicine test for esophageal pinch biopsies identifies high risk non-dysplasti Read More
TissueCypher® Further Validated to Accurately Risk Stratify Barrett’s Esophagus Patients with Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences
Data presented at ACG, UEGW illustrates the 4th independent validation of TissueCypher performance for risk stratify Read More
Cernostics Announces Formation of Distinguished Medical Advisory Board Including Top Specialists in All Facets of Esophageal Disease
PITTSBURGH, Penn., July 1, 2019 — Cernostics, developer of next-generation cancer diagnostics Read More
Objective risk assessment guides surveillance and treatment
Patients with Barrett’s es Read More
– US and EU patents for TissueCypher® cover methods for detecting risk of
progression to esophageal cance Read More
– TissueCypher® Barrett’s Esophagus Assay is First Precision Medicine Platform for Prevention of Esophageal Read More
– New Commercial Leader Positions Company for Continued Success and Growth –
BETHLEHEM Read More